Urology Case Reports (Jul 2016)
Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer
Abstract
The Prostate Health Index (phi) has been FDA approved for decision-making regarding prostate biopsy. Phi has additionally been shown to positively correlate with tumor volume, extraprostatic disease and higher Gleason grade tumors. Here we describe a case in which an elevated phi encouraged biopsy of a gentleman undergoing active surveillance leading to reclassification of his disease as high risk prostate cancer.
Keywords